topical pimecrolimus cream 1%	triamcinolone acetonide oral paste 0.1%	improvement in symptom scores	1792	1893	there was a statistically highly significant improvement in reduction of clinical scoring (P < 0.01%)
topical pimecrolimus cream 1%	triamcinolone acetonide oral paste 0.1%	reduction in erythematous area	1636	1786	there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07)
pimecrolimus	triamcinolone acetate	reappearance of erythematous areas after 2 months posttreatment	12745	12973	After the posttreatment follow-up of 2 months, the erythematous areas reappeared in 6.7% and 33.3% subjects in the pimecrolimus and triamcinolone acetonide groups, respectively, but no statistical difference was found (P = 0.07)
topical pimecrolimus cream 1%	triamcinolone acetonide oral paste 0.1%	reduction in burning sensation	1636	1753	there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18)
topical pimecrolimus cream 1%	triamcinolone acetonide oral paste 0.1%	reduction in erythematous area	1610	1786	On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18) and erythematous area (P = 0.07)
topical pimecrolimus cream 1%	triamcinolone acetonide oral paste 0.1%	reduction in burning sensation	1610	1753	On intergroup comparison, there was no statistically significant difference between the groups in the reduction in burning sensation (P = 0.18)
